GASTROINTESTINAL STROMAL TUMOR
Clinical trials for GASTROINTESTINAL STROMAL TUMOR explained in plain language.
Never miss a new study
Get alerted when new GASTROINTESTINAL STROMAL TUMOR trials appear
Sign up with your email to follow new studies for GASTROINTESTINAL STROMAL TUMOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immunotherapy duo takes on rare tumors
Disease control OngoingThis phase 2 trial is testing a combination of two immunotherapy drugs, nivolumab and ipilimumab, in 798 people with over 50 types of rare cancers. The goal is to see if these drugs can shrink tumors by helping the immune system attack cancer cells. Participants receive the drugs…
Matched conditions: GASTROINTESTINAL STROMAL TUMOR
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for Drug-Resistant stomach cancer? sorafenib trial underway
Disease control OngoingThis phase 2 trial tests the drug sorafenib in 38 patients with gastrointestinal stromal tumor (GIST) that has worsened despite treatment with imatinib and sunitinib. Sorafenib works by blocking enzymes that help tumors grow and by cutting off blood supply to the cancer. The stud…
Matched conditions: GASTROINTESTINAL STROMAL TUMOR
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Experts unite to make cancer trial results easier to compare
Knowledge-focused OngoingThis study brings together cancer experts to agree on standard definitions for key measurements used in cancer clinical trials, such as how long patients live without their cancer getting worse. Currently, different trials define these measurements in different ways, making it ha…
Matched conditions: GASTROINTESTINAL STROMAL TUMOR
Sponsor: Institut Bergonié • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC